Trial · NCT06462014
Outcomes11
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants According to Geographic Region | Baseline period = Up to 1 year prior to index date; available data observed retrospectively over 178 days in this study | Analysis population included all eligible participants whose data was retrieved and observed in this retrospective observational study. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants According to Index Year | At Index date (anytime between 18-Dec-2020 to 31-Dec- 2023 [approximately 3 years]; available data observed retrospectively over 178 days in this study | Analysis population included all eligible participants whose data was retrieved and observed in this retrospective observational study. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Time From First Observed Prostate Cancer Diagnosis Date to the Index Date | From prostate cancer diagnosis to index date (approximately maximum up to 18 years); available data observed retrospectively over 178 days in this study | Analysis population included all eligible participants whose data was retrieved and observed in this retrospective observational study. | Months | MEAN |
| PRIMARY | Number of Participants According to Type of Previous Treatments Received | Baseline period = Up to 1 year prior to index date; available data observed retrospectively over 178 days in this study | Analysis population included all eligible participants whose data was retrieved and observed in this retrospective observational study. All the participants of the study were analyzed but not all participants might have contributed to the data reported. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants According to Metastasis Status | Baseline period = Up to 1 year prior to index date or within 90 days after the index date; available data observed retrospectively over 178 days in this study | Analysis population included all eligible participants whose data was retrieved and observed in this retrospective observational study. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants According to Site of Metastasis | Baseline period = Up to 1 year prior to index date or within 90 days after the index date; available data observed retrospectively over 178 days in this study | Analysis population included all eligible participants whose data was retrieved and observed in this retrospective observational study. Here, Overall Number of Participants Analyzed signifies number of participants evaluable for this outcome measure. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants According to Androgen Deprivation Therapy (ADT) Status | Any time prior to index date including baseline period (approximately maximum up to 18 years); available data observed retrospectively over 178 days in this study | Analysis population included all eligible participants whose data was retrieved and observed in this retrospective observational study. Here, Number Analyzed signifies number of participants evaluable for the specified rows. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Prostate-Specific Antigen (PSA) Value at 180 Days Prior to Index Date | 180 days prior to Index date; data observed retrospectively over 178 days in this study | Analysis population included all eligible participants whose data was retrieved and observed in this retrospective observational study. Here, 'Overall Number of Participants Analyzed' signifies number of participants evaluable for this outcome measure. | Nanograms per milliliter | MEAN |
| PRIMARY | Testosterone Value at 180 Days Prior to Index Date | 180 days prior to Index date; data observed retrospectively over 178 days in this study | Analysis population included all eligible participants whose data was retrieved and observed in this retrospective observational study. Here, 'Overall Number of Participants Analyzed' signifies number of participants evaluable for this outcome measure. | Nanograms per deciliter | MEAN |
| PRIMARY | Mean National Cancer Institute (NCI) Charlson Comorbidity Index (CCI) Score | Baseline period = Up to 1 year prior to index date or within 90 days after the index date; available data observed retrospectively over 178 days in this study | Analysis population included all eligible participants whose data was retrieved and observed in this retrospective observational study. | Units on a scale | MEAN |
| PRIMARY | Number of Participants According to Comorbidities | Baseline period = Up to 1 year prior to index date or within 90 days after the index date; available data observed retrospectively over 178 days in this study | Analysis population included all eligible participants whose data was retrieved and observed in this retrospective observational study. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06462014/outcomes